

## Product datasheet for RC209743L2V

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## EPM2A (NM\_005670) Human Tagged ORF Clone Lentiviral Particle

## **Product data:**

**Product Type:** Lentiviral Particles

**Product Name:** EPM2A (NM\_005670) Human Tagged ORF Clone Lentiviral Particle

Symbol: EPM2A

Synonyms: EPM2; MELF

Mammalian Cell

Selection:

None

**Vector:** pLenti-C-mGFP (PS100071)

Tag: mGFP

**ACCN:** NM\_005670

ORF Size: 993 bp

**ORF Nucleotide** 

The ORF insert of this clone is exactly the same as(RC209743).

Sequence:

OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally accurring variations (e.g. polymorphisms), each with its own valid existence. This

naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing

variants is recommended prior to use. More info

**OTI Annotation:** This clone was engineered to express the complete ORF with an expression tag. Expression

varies depending on the nature of the gene.

**RefSeg:** NM 005670.3

 RefSeq Size:
 3474 bp

 RefSeq ORF:
 996 bp

 Locus ID:
 7957

 UniProt ID:
 095278

Cytogenetics: 6q24.3

**Domains:** DSPc

**Protein Families:** Druggable Genome, Phosphatase





ORIGENE

**MW:** 37 kDa

**Gene Summary:** 

This gene encodes a dual-specificity phosphatase and may be involved in the regulation of glycogen metabolism. The protein acts on complex carbohydrates to prevent glycogen hyperphosphorylation, thus avoiding the formation of insoluble aggregates. Loss-of-function mutations in this gene have been associated with Lafora disease, a rare, adult-onset recessive neurodegenerative disease, which results in myoclonus epilepsy and usually results in death several years after the onset of symptoms. The disease is characterized by the accumulation of insoluble particles called Lafora bodies, which are derived from glycogen. [provided by RefSeq, Jan 2018]